These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27866156)

  • 1. Hide-and-seek: the interplay between cancer stem cells and the immune system.
    Sultan M; Coyle KM; Vidovic D; Thomas ML; Gujar S; Marcato P
    Carcinogenesis; 2017 Feb; 38(2):107-118. PubMed ID: 27866156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype.
    Ames E; Canter RJ; Grossenbacher SK; Mac S; Chen M; Smith RC; Hagino T; Perez-Cunningham J; Sckisel GD; Urayama S; Monjazeb AM; Fragoso RC; Sayers TJ; Murphy WJ
    J Immunol; 2015 Oct; 195(8):4010-9. PubMed ID: 26363055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bad seed: Cancer stem cells in tumor development and resistance.
    Koren E; Fuchs Y
    Drug Resist Updat; 2016 Sep; 28():1-12. PubMed ID: 27620951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells.
    Ahmed N; Escalona R; Leung D; Chan E; Kannourakis G
    Semin Cancer Biol; 2018 Dec; 53():265-281. PubMed ID: 30317036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells.
    Hirohashi Y; Torigoe T; Inoda S; Takahashi A; Morita R; Nishizawa S; Tamura Y; Suzuki H; Toyota M; Sato N
    Immunotherapy; 2010 Mar; 2(2):201-11. PubMed ID: 20635928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.
    Kozlowska AK; Kaur K; Topchyan P; Jewett A
    Cancer Immunol Immunother; 2016 Jul; 65(7):835-45. PubMed ID: 27034236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer stem cell mimicry for immune evasion and therapeutic resistance.
    Saw PE; Liu Q; Wong PP; Song E
    Cell Stem Cell; 2024 Aug; 31(8):1101-1112. PubMed ID: 38925125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy.
    Luna JI; Grossenbacher SK; Murphy WJ; Canter RJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):313-324. PubMed ID: 27960589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source.
    Ruiu R; Tarone L; Rolih V; Barutello G; Bolli E; Riccardo F; Cavallo F; Conti L
    Prog Mol Biol Transl Sci; 2019; 164():119-188. PubMed ID: 31383404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways.
    Leon G; MacDonagh L; Finn SP; Cuffe S; Barr MP
    Pharmacol Ther; 2016 Feb; 158():71-90. PubMed ID: 26706243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure.
    Galassi C; Musella M; Manduca N; Maccafeo E; Sistigu A
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor dormancy and cancer stem cells: two sides of the same coin?
    Kleffel S; Schatton T
    Adv Exp Med Biol; 2013; 734():145-79. PubMed ID: 23143979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour Cell Secretome in Chemoresistance and Tumour Recurrence.
    Madden EC; Gorman AM; Logue SE; Samali A
    Trends Cancer; 2020 Jun; 6(6):489-505. PubMed ID: 32460003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approaches for targeting cancer stem cells drug resistance.
    Rosa R; D'Amato V; De Placido S; Bianco R
    Expert Opin Drug Discov; 2016 Dec; 11(12):1201-1212. PubMed ID: 27700193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers.
    Lei MML; Lee TKW
    Front Cell Dev Biol; 2021; 9():692940. PubMed ID: 34235155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches.
    Pan Q; Li Q; Liu S; Ning N; Zhang X; Xu Y; Chang AE; Wicha MS
    Stem Cells; 2015 Jul; 33(7):2085-92. PubMed ID: 25873269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical and therapeutic implications of cancer stem cell biology.
    Cheng L; Alexander R; Zhang S; Pan CX; MacLennan GT; Lopez-Beltran A; Montironi R
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):1131-43. PubMed ID: 21806335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?
    Plaks V; Kong N; Werb Z
    Cell Stem Cell; 2015 Mar; 16(3):225-38. PubMed ID: 25748930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoints in tumor microenvironment and their relevance to the development of cancer stem cells.
    Khosravi N; Mokhtarzadeh A; Baghbanzadeh A; Hajiasgharzadeh K; Shahgoli VK; Hemmat N; Safarzadeh E; Baradaran B
    Life Sci; 2020 Sep; 256():118005. PubMed ID: 32593711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells.
    Mu Q; Najafi M
    Int Immunopharmacol; 2021 Sep; 98():107895. PubMed ID: 34171623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.